Cargando…

Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis

OBJECTIVES: Mavrilimumab, a human monoclonal antibody targeting the alpha subunit of the granulocyte-macrophage colony-stimulating factor receptor, was evaluated in a phase 2 randomised, double-blind, placebo-controlled study to investigate efficacy and safety in subjects with rheumatoid arthritis (...

Descripción completa

Detalles Bibliográficos
Autores principales:	Burmester, Gerd R, Weinblatt, Michael E, McInnes, Iain B, Porter, Duncan, Barbarash, Olga, Vatutin, Mykola, Szombati, Istvan, Esfandiari, Ehsanollah, Sleeman, Matthew A, Kane, Christopher D, Cavet, Guy, Wang, Bing, Godwood, Alex, Magrini, Fabio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2013
Materias:	Clinical and Epidemiological Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3756523/ https://www.ncbi.nlm.nih.gov/pubmed/23234647 http://dx.doi.org/10.1136/annrheumdis-2012-202450

Ejemplares similares

A Randomized Phase IIb Study of Mavrilimumab and Golimumab in Rheumatoid Arthritis
por: Weinblatt, Michael E., et al.
Publicado: (2017)

Mavrilimumab, a Fully Human Granulocyte–Macrophage Colony‐Stimulating Factor Receptor α Monoclonal Antibody: Long‐Term Safety and Efficacy in Patients With Rheumatoid Arthritis
por: Burmester, Gerd R., et al.
Publicado: (2018)

Mavrilimumab, a human monoclonal antibody targeting GM-CSF receptor-α, in subjects with rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase I, first-in-human study
por: Burmester, Gerd R, et al.
Publicado: (2011)

Spotlight on mavrilimumab for the treatment of rheumatoid arthritis: evidence to date
por: Crotti, Chiara, et al.
Publicado: (2017)

Mavrilimumab: an evidence based review of its potential in the treatment of rheumatoid arthritis
por: Di Franco, Manuela, et al.
Publicado: (2014)

Mavrilimumab for severe COVID-19
por: Khan, Adil Rashid, et al.
Publicado: (2020)

Mavrilimumab for severe COVID-19
por: Pourhoseingholi, Mohamad Amin, et al.
Publicado: (2020)

Mavrilimumab for severe COVID-19 – Authors' reply
por: De Luca, Giacomo, et al.
Publicado: (2020)

Low-dose prednisone chronotherapy for rheumatoid arthritis: a randomised clinical trial (CAPRA-2)
por: Buttgereit, Frank, et al.
Publicado: (2013)

Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis
por: Gabay, Cem, et al.
Publicado: (2016)

Model‐Based Discovery and Development of Biopharmaceuticals: A Case Study of Mavrilimumab
por: Wang, Bing, et al.
Publicado: (2017)

Neutropaenia in early rheumatoid arthritis: frequency, predicting factors, natural history and outcome
por: Fragoulis, George E, et al.
Publicado: (2018)

Identification of Urinary Peptide Biomarkers Associated with Rheumatoid Arthritis
por: Stalmach, Angelique, et al.
Publicado: (2014)

Association of hemoglobin levels with radiographic progression in patients with rheumatoid arthritis: an analysis from the BRASS registry
por: Shadick, Nancy, et al.
Publicado: (2023)

Future therapeutic targets in rheumatoid arthritis?
por: Cheung, Tommy Tsang, et al.
Publicado: (2017)

Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNFα inhibitors and rituximab
por: Listing, Joachim, et al.
Publicado: (2015)

Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study
por: McInnes, Iain B, et al.
Publicado: (2015)

Depression and anxiety in an early rheumatoid arthritis inception cohort. associations with demographic, socioeconomic and disease features
por: Fragoulis, George E, et al.
Publicado: (2020)

Carbamylation of vimentin is inducible by smoking and represents an independent autoantigen in rheumatoid arthritis
por: Ospelt, Caroline, et al.
Publicado: (2017)

Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial
por: Burmester, Gerd R, et al.
Publicado: (2016)

Characteristics of rheumatoid arthritis and its association with major comorbid conditions: cross-sectional study of 502 649 UK Biobank participants
por: Siebert, Stefan, et al.
Publicado: (2016)

Adalimumab long-term safety: infections, vaccination response and pregnancy outcomes in patients with rheumatoid arthritis
por: Burmester, Gerd R, et al.
Publicado: (2017)

Mild COVID-19 despite inadequate antibody response after repeated vaccinations in rheumatic disease patients with rituximab-induced B cell depletion: a case series
por: ten Hagen, Alexander, et al.
Publicado: (2022)

Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis
por: Kerschbaumer, Andreas, et al.
Publicado: (2020)

Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA)
por: Burmester, Gerd R, et al.
Publicado: (2010)

Interleukin-18: a therapeutic target in rheumatoid arthritis?
por: McInnes, Iain B, et al.
Publicado: (2005)

Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease
por: Burmester, Gerd R, et al.
Publicado: (2013)

Effectiveness of Mavrilimumab in Viral Infections Including SARS-CoV-2 Infection - A Brief Review
por: Bhatt, Kinal, et al.
Publicado: (2021)

The US7 score is sensitive to change in a large cohort of patients with rheumatoid arthritis over 12 months of therapy
por: Backhaus, Tina M, et al.
Publicado: (2013)

JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis
por: Fragoulis, George E, et al.
Publicado: (2019)

Certolizumab pegol plus methotrexate provides broad relief from the burden of rheumatoid arthritis: analysis of patient-reported outcomes from the RAPID 2 trial
por: Strand, Vibeke, et al.
Publicado: (2011)

Tocilizumab combination therapy or monotherapy or methotrexate monotherapy in methotrexate-naive patients with early rheumatoid arthritis: 2-year clinical and radiographic results from the randomised, placebo-controlled FUNCTION trial
por: Burmester, Gerd R, et al.
Publicado: (2017)

Changes in Plasma Itaconate Elevation in Early Rheumatoid Arthritis Patients Elucidates Disease Activity Associated Macrophage Activation
por: Daly, Rónán, et al.
Publicado: (2020)

Sirukumab, a human anti-interleukin-6 monoclonal antibody: a randomised, 2-part (proof-of-concept and dose-finding), phase II study in patients with active rheumatoid arthritis despite methotrexate therapy
por: Smolen, Josef S, et al.
Publicado: (2014)

Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA)
por: Dougados, Maxime, et al.
Publicado: (2014)

Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naïve patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study
por: Emery, P, et al.
Publicado: (2017)

Sustained improvements in MRI outcomes with abatacept following the withdrawal of all treatments in patients with early, progressive rheumatoid arthritis
por: Peterfy, Charles, et al.
Publicado: (2016)

Time-varying risks of infection in patients as they proceed through the phases of ‘pre-RA’: results from the Scottish Early RA inception cohort
por: Porter, Duncan, et al.
Publicado: (2023)

Effect of IL-6 receptor blockade on high-sensitivity troponin T and NT-proBNP in rheumatoid arthritis
por: Welsh, Paul, et al.
Publicado: (2016)

Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial
por: Schiff, Michael, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_pv4avb2bql6jc6505ava1eh4li